Author:
Demirhan Timur,Guksu Elif,Yazar Yücel,Keskin Elif,Bellur Atici Esen,Özkan Sibel A.
Reference30 articles.
1. Eltrombopag (Promacta), A thrombopoetin receptor agonist for the treatment of thrombocytopenia: current and future considerations;Serebruany;Am. J. Ther.,2010
2. Eltrombopag for use in children with immune thrombocytopenia;Kim;Blood Adv.,2018
3. Eltrombopag in immune thrombocytopenia: Efficacy review and update on drug safety;Gonzalez-Porras;Ther. Adv. Drug Saf.,2018
4. Metabolism and disposition of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, in healthy human subjects;Deng;Drug. Metab. Dispos.,2011
5. Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study;Kawaguchi;J. Gastroenterol.,2012